Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
3.620
-0.020 (-0.55%)
Nov 28, 2025, 1:00 PM EST - Market closed
MRVI Analyst Ratings
Total Analysts
7
Consensus Rating
Buy
Price Target
$4.54
Upside
+25.41%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $10 → $5 | Strong Buy | Maintains | $10 → $5 | +38.12% | Aug 12, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +38.12% | Aug 12, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +176.24% | May 13, 2025 |
| Baird | Baird | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | -44.75% | May 13, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $7 → $5 | Hold | Maintains | $7 → $5 | +38.12% | Mar 25, 2025 |
| UBS | UBS | Hold Maintains $8 → $2.5 | Hold | Maintains | $8 → $2.5 | -30.94% | Mar 21, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +120.99% | Mar 3, 2025 |
| Baird | Baird | Buy → Hold Downgrades $9 → $3 | Buy → Hold | Downgrades | $9 → $3 | -17.13% | Feb 26, 2025 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Sell Downgrades $7 → $4.25 | Hold → Strong Sell | Downgrades | $7 → $4.25 | +17.40% | Dec 5, 2024 |
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Nov 14, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $17 → $13 | Buy | Maintains | $17 → $13 | +259.12% | Nov 8, 2024 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 8, 2024 |
| Baird | Baird | Buy Maintains $10 → $9 | Buy | Maintains | $10 → $9 | +148.62% | Nov 8, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $8 → $7 | Hold | Maintains | $8 → $7 | +93.37% | Oct 8, 2024 |
| Wells Fargo | Wells Fargo | Buy Initiates $10 | Buy | Initiates | $10 | +176.24% | Aug 27, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $15 | Buy | Reiterates | $15 | +314.36% | Aug 16, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.